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The primary abnormality in chronic obstructive pulmonary disease (COPD) is chronic airway
inflammation which results in airflow limitation. Disease progression is usually depicted as
an accelerated decline in FEV1 over time. However, COPD patients also manifest progressive
static hyperinflation due to the combined effects of reduced lung elastic recoil and increased
airway resistance. Superimposed on static hyperinflation are further increases in operational
lung volumes (dynamic hyperinflation) brought on during exercise, exacerbations or
tachypnea.
An important consequence of exertional dyspnea is activity limitation. COPD patients have
been shown to spend only a third of the day walking or standing compared with age-matched
healthy individuals who spend more than half of their time in these activities. Furthermore,
the degree of activity limitation measured by an accelerometer worsens with disease progres-
sion. COPD patients have been shown to have an accelerated loss of aerobic capacity (VO2max)
and this correlates with mortality just as is seen with hypertension, diabetes and obesity. Thus
physical inactivity is an important therapeutic target in COPD.
Summarizing; airflow obstruction leads to progressive hyperinflation, activity limitation,
physical deconditioning and other comorbidities that characterize the COPD phenotype. Tar-
geting the airflow obstruction with long-acting bronchodilator therapy in conjunction with
a supervised exercise prescription is currently the most effective therapeutic intervention in
earlier COPD. Other important manifestations of skeletal muscle dysfunction include muscle
atrophy and weakness. These specific problems are best addressed with resistance training
with consideration of anabolic supplementation.
ª 2008 Elsevier Ltd. All rights reserved.206 8211.
ucla.edu
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moderation and exercised in labours in which each is
accustomed, become thereby healthy, well-developed,
and age more slowly, but if unused and left idle they
become quickly liable to disease, defective in growth,
and age more quickly.’’ Hippocrates. Circa 450 BC.
Introduction
Chronic obstructive pulmonary disease (COPD) is a leading
cause of morbidity and mortality worldwide. The reported
incidence of COPD is believed to dramatically under-
represent the total burden of the disease because typically
the diagnosis is not established until patients become
symptomatic. At this point, the condition is usually
moderately advanced, as COPD is known to begin decades
before symptoms manifest.1 COPD is the fourth-leading
cause of death in the USA and Europe, and COPD mortality
in females has more than doubled over the last 40 years.2
Interestingly, due to a widespread misperception that COPD
primarily affects males, there is evidence of a diagnostic
gender bias: in that when physicians are presented with
patients with the same age and history but different
gender, they diagnose COPD more frequently in men than
women.3
The spiral of decline in COPD is characterized by
progressively decreased physical functioning and progres-
sive symptoms that eventually require hospital admission as
the disease progresses. Patients often are unable to work
and may become socially isolated, sleep deprived, and
depressed.4 Adding to these stressors is the continuous fear
of exacerbations, which seem to contribute to the
progressive decline in lung function, physical status and
quality of life.4
Manifestations of COPD are highly variable, with signifi-
cant differences in functional capacity, dyspnea, and
involuntary weight loss from patient to patient.5 Each of
these clinical features, individually and collectively,
contribute to the COPD phenotype. Inactivity, decondition-
ing, and muscle atrophy all lead to a decrease in functional
capacity. Hyperinflation, hypoxemia, anxiety, and increased
ventilatory drive contribute to dyspnea but also decondi-
tioning can exacerbate dyspnea by increasing the ventila-
tory requirement for a given level of exercise. The additional
work of breathing required to overcome the increasedairway resistance can significantly increase the oxygen
consumption of the respiratory muscles, increasing meta-
bolic rate and contributing to involuntary weight loss.6
Finally, muscle disuse and atrophy result in loss of lean body
mass, whilst malnutrition further exacerbates involuntary
weight loss. The common contributory feature of all of these
patient outcomes is physical inactivity. Thus physical inac-
tivity is an important therapeutic target in COPD.
Hyperinflation is central in the
pathophysiology of COPD
Hyperinflation, which can occur even in mild to moderate
cases,7 explains many of the pathophysiological manifes-
tations of COPD and also correlates with important patient-
reported outcomes, such as dyspnea, declining exercise
performance, and reduced quality of life.8The exertional
dyspnea leads to limitation of daily activities which begins
insidiously but progresses relentlessly over time. COPD
patients with an average age of 64 years have been shown
to spend only a third of the day walking or standing
compared with age-matched healthy individuals who spend
more than half of their time in these activities.9 The
worsening inactivity leads to an accelerated decline in
aerobic performance with disease progression. COPD
patients have been shown to have a faster decline in
aerobic capacity.10 Furthermore, in this cohort of 150 male
COPD patients, the reduced aerobic capcity correlated with
increased mortality.10 The same phenomenon is seen with
hypertension, diabetes and obesity.11
Spirometry is important to establish the diagnosis of
COPD and should be considered in symptomatic patients
with a history of significant exposures such as tobacco
smoking (GOLD). Spirometry detects airflow limitation
which has been defined as a low FEV1/forced vital capacity
(FVC) ratio less than 70%.11 Spirometry also provides
a measure of the forced expiratory volume in 1 s (FEV1)
which has been used in several published guidelines to
stage COPD severity (ATS/ERS, BTS, CTS).12e14 Although
FEV1 serves a useful purpose in the diagnosis and staging of
COPD,15 this measure correlates poorly with exercise
performance16 and patient-reported outcomes such as
dyspnea and quality of life.17 For example, in the National
Emphysema Treatment Trial (NETT) which enrolled aprox-
imately 1200 subjects, FEV1 significantly correlated with
Figure 1 Relationship between FEV1 and exercise performance in NETT. Data from the National Emphysema Treatment Trial
(NETT). (Right) Relation between forced expiratory volume in 1 s (FEV1) and maximum oxygen consumption (VO2max). A correlation
was found (rZ 0.65), but the range of possible values for (VO2max) varied widely at a given level of FEV1. (Left) The relation
between FEV1 and functional exercise capacity as measured by 6-min walk distance. In this case there is no meaningful correlation.
18
(Figure originally appeared in Ref. 8. Reproduced with permission.)
Airflow obstruction and exercise 327maximum exercise capacity (rZ 0.65), however, a given
value of FEV1 can be seen to be poorly predictive of exer-
cise capacity (Fig. 1, panel B). Furthermore, FEV1 showed
no correlation with 6-min walking distance (rZ 0.38),
a measure of functional exercise capacity.18 These data
also confirm our clinical experience that once FEV1 is
reduced to 35% of predicted, exercise capability is highly
variable: some patients experience minimal physical limi-
tations, while others are not able to walk. It can be argued,
therefore, that clinicians should look beyond the FEV1 to
assess and manage COPD.
The central connection between lung function
measures, exercise capabilities, and COPD symptoms
appears to be not FEV1, but the pathophysiologic
phenomenon of hyperinflation. Hyperinflation, is usually
defined as the elevation of total lung capacity (TLC),
functional residual capacity (FRC) or end expiratory lung
volume (EELV) and residual volume (RV). For accuracy,
these volumes should be measured by body plethysmog-
raphy. It has been shown that as FEV1 declines, hyperin-
flation increases (Fig. 2).16 Given that static hyperinflation
is a progressive phenomenon and a fundamental factor in
disease progression, assessment of the development and80
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Figure 2 Hyperinflation and FEV1. Foglio et al.
16 (Figure
originally appeared in Ref. 8. Reproduced with permission.)extent of hyperinflation may in fact be a better indicator of
disease progression than FEV1.
The central role of air trapping and hyperinflation in
patient functioning and outcomes is illustrated in Fig. 3. At
play are two vicious cycles that act to worsen hyperinfla-
tion. The first cycle results from activity limitation, leading
to deconditioning, defined as the premature accumulation
of lactate at low exercise work rates. Lactate from decon-
ditioned muscles effluxes into the bloodstream, increasing
carbon dioxide production from bicarbonate buffering,
which in turn increases the ventilatory requirement for
exercise. Increased ventilatory requirement is a significant
factor in worsening air trapping and hyperinflation, which
then manifests as increased dyspnea and reduced exercise
tolerance. COPD exacerbations worsen airflow obstruction
and also cause hyperinflation even before it becomes clin-
ically apparent. The second cycle (Fig. 3) revolves around
respiratory rate and available exhalation time. For given
values of airway resistance and elastic recoil, when exha-
lation time is shortened due to increased inspiratory rate
there is incomplete lung emptying, i.e. worsened air trap-
ping and hyperinflation. These events can be triggered by
anxiety or hypoxemia both of which cause breathing to
become rapid and shallow. Understanding Fig. 3 highlights
the important therapeutic targets that should lessen
hyperinflation and improve patient-reported outcomes.
These are to (a) relieve airflow obstruction, (b) prevent
exacerbations, (c) improve physical conditioning, (d)
correct hypoxemia, and (e) prevent anxiety and panic
attacks. These therapeutic approaches are readily recog-
nized as the long-established goals of a traditional pulmo-
nary rehabilitation program.
Lung volume response to exercise
The behavior of operational lung volumes during exercise
differs between healthy individuals and those with COPD.
When healthy individuals exercise, tidal volume (VT)
expands by virtue of a decrease in the end expiratory lung
volume and an increase in the end-inspiratory lung volume.
Also, the operational lung volumes (EELVeEILV) remain on
the steeper part of the pressureevolume or compliance
COPD
Hypoxemia Airflow obstruction Exacerbations
Anxiety
Tachypnea ↑ Ventilatory
requirement
Dyspnea Activity limitation
Poor health-related quality of life
Deconditioning
Air trapping
Hyperinflation
Patient
Reported
Outcomes
Figure 3 Air trapping links pathophysiology and patient centered outcomes in COPD. Central role of air trapping and hyperin-
flation in the pathophysiology of chronic obstructive pulmonary disease (COPD). Although related to increased airway resistance,
hyperinflation correlates more directly with patient-reported outcomes. Activity limitation leads to deconditioning, which, in turn,
increases ventilatory requirement, establishing a cycle of decline leading to worsening hyperinflation. Anxiety and hyopoxemia
cause tachypnea, which worsens hyperinflation by allowing less time for exhalation. [Figure originally appeared in Ref. 8.
Reproduced with permission.]
328 C.B. Coopercurve for the respiratory system. By contrast, in patients
with COPD, as respiratory rate increases during exercise,
end expiratory lung volume also increases: a phenomenon
called dynamic hyperinflation. A consequence of dynamic
hyperinflation is that the operational lung volumes are
forced upwards onto the flatter part of the pressuree
volume curve, increasing the elastic work of breathing. As
a direct consequence of increased EELV, the inspiratory
capacity (IC) is decreased. Dynamic hyperinflation is com-
pounded with pre-existing static hyperinflation, worsening
dyspnea further and leaving the patient with the feeling
that there is no room to breathe. The extent of dyspnea is
closely related to the degree of dynamic hyperinflation.19
Progressive dynamic hyperinflation, which can occur even
during simple daily activities such as walking,20 contributes
to ventilatory constraints that limit exercise and contrib-
utes to dyspnea intensity.19
The medical literature has shown that even in mild cases
of COPD there is evidence of hyperinflation. In a study of the
effects of mild-to-moderate airflow limitation on exercise
capacity as experienced in COPD, 9 control subjects with
normal pulmonary function and 12 patients with mild-to-
moderate airflow limitation were compared during
progressive cycle ergometry.7 FEV1 values (% predicted) for
the control group were 105% and for the mild COPD group
were 72%; aerobic capacity ormaximum oxygen intake ( _VO2)
was 104% for the control group and 69% for the COPD group.
These data show that even in mild cases of COPD, the
aerobic capacity is decreased. Comparing rest, to maximal
exercise, a significant decrease in end expiratory lung
volume (p< 0.01) was noted in control subjects, while
a significant increase (p< 0.05) was found in the COPD
group. This increase in end expiratory lung volume experi-
enced by the COPD group reflects dynamic hyperinflation
and can be attributed to the effect of even mild airflow
limitation on the ventilatory response to exercise.Dynamic hyperinflation is targeted with therapeutic
interventions to improve lung emptying or reduce ventila-
tory demand in order to produce a clinically meaningful
improvement of exercise endurance and symptoms. To
determine which resting spirometric parameters best reflect
improvements in exercise tolerance and exertional dyspnea
in response to acute high-dose anticholinergic therapy in
advanced COPD, O’Donnell et al.21 studied 29 patients with
stable COPD and moderate to severe chronic dyspnea who
received 500 mg of nebulized ipratropium bromide or
placebo. The study reported that inspiratory capacity (TLCe
EELV) was the best correlate of exercise performance and
argued that this was a representative measure of the degree
of hyperinflation. In another study of the effects of bron-
chodilator therapy on hyperinflation, O’Donnell et al.22
showed that patients stopped exercise when the inspiratory
reserve volume reached a level of approximately 500 ml
below total lung capacity regardless of whether they were
given salmeterol or placebo. These findings are indicative of
a dyspnea threshold during which patients stray off the
steep part of the pressure volume curves and experience
very unfavorable respiratory system mechanics that lead
them to stop exercise. From a clinical standpoint, the
objective is to keep people in the mid-range (steeper part)
of their compliance curve in order to minimize dyspnea.
Interventions that prolong the time needed to reach oper-
ational lung volumes that result in dyspnea are believed to
improve exercise endurance. These interventions are dis-
cussed in the following paragraphs.
Non-pharmacologic interventions
In the context of COPD management in general, there
are several important non-pharmacological interventions
including avoidance of exposures, vaccinations, structured
rehabilitative exercise, oxygen supplementation and several
Airflow obstruction and exercise 329surgical approaches including lung transplantation. Most of
these issues are beyond the scope of this article and have
been thoroughly explored in other publications.12,23
However, important investigation has been undertaken to
determine the effects of certain non-pharmacologic inter-
ventions on hyperinflation, exercise, and dyspnea (Table 1).
Rehabilitative exercise, heliumeoxygen breathing, and lung
volume-reduction surgery have been shown to impact
hyperinflation to some small degree.24e30 In the study by
Porszasz et al.24 seven weeks of exercise training at target
work rates resulted in lower minute ventilation and
breathing frequency at the same constant work rate along
with increased IC by 133 ml (p< 0.05) signifying decreased
hyperinflation. An earlier study had demonstrated similar
improvements in breathing efficiency (minute ventilation
and breathing frequency) after a rehabilitative exercise
program.31 Breathing heliumeoxygen mixture as opposed to
ordinary air should improve expiratory flow because of the
lower gas density and thus reduce air trapping and hyper-
inflation. One study demonstrated this effect quite
convincingly during constant load exercise with reductions
in IC reflecting improvement in dynamic hyperinflation.25
However, another study at rest showed heliumeoxygen
breathing to have no effect on hyperinflation as compared to
bronchodilator therapy.26 Supplemental oxygen has been
shown to be more effective, especially for its effects on
dynamic hyperinflation during exercise. For example, Som-
fay et al.46 showed improvements in dynamic IC up to 330 ml
during exercise breathing 50% oxygen. The efficacy reported
for supplemental oxygen is almost certainly due to a slowing
of the respiratory rate resulting from higher arterial oxygen
partial pressure, which reduces the peripheral chemore-
ceptor or carotid body component of ventilatory drive.
Effects of bronchodilators on respiratory
mechanics during exercise
Bronchodilators work to relieve hyperinflation and dyspnea
by relaxing airway smooth muscle thus reducing airway
resistance and increasing expiratory flow at a given lungTable 1 Effects of non-pharmacological interventions on hyper
Intervention Author n Baseline
FEV1 (%)
D Static
ICa (mL)
D
IC
Oxygen Somfay et al.46 10 31 31 þ
Exercise
training
Porszasz et al.24 24 36 NM þ
LVRs Fishman et al.27 608 27 NM N
Appleton et al.28 29 28 NM N
Miller et al.29 93 15e40 NM N
Heliox Palange et al.25 12 37 80 þ
Pecchiari et al.26 22 41e61 þ20 N
BLVR Hopkinson et al.30 19 28 NM þ
NMZ not measured; BLVRZ bronchoscopic lung volume reduction. [S
a Measured during body plethysmography as TLCeFRC.
b Measured at isotime during constant load sub-maximal exercise.
c Measured with 50% inspired oxygen concentration.volume. To test the efficacy of tiotropium in achieving the
goal of sustained reduction in lung hyperinflation in
patients with COPD, a double-blinded, placebo-controlled,
parallel-group study was conducted in 187 patients
randomized to receive either 18 mg of tiotropium or
placebo.32 Spirometry, plethysmographic lung volumes,
cycle exercise endurance and the intensity of exertional
dyspnea at 75% of each patient’s maximal work capacity
were compared. The study showed that inspiratory
capacity increased 0.33 L with treatment; in contrast,
residual volume and functional residual capacity
decreased, thereby reducing hyperinflation both at rest and
during exercise. Because improved inspiratory capacity
permitted greater expansion of tidal volume, exercise
endurance was prolonged by 21% following treatment,
compared to placebo.32
The effects of bronchodilators on static and dynamic
hyperinflation, exercise endurance, and dyspnea in the
setting of COPD are well documented in the medical liter-
ature (Table 2),26e33 but the exact mechanisms by which
bronchodilators improve exercise performance are unclear.
Notably, by altering lung mechanics, bronchodilatory
therapy has been reported to change patient perceptions of
symptoms during exercise.33 Whereas prior to treatment
patients reported that breathlessness limited their physical
activity, following treatment they were more likely to
report limitation due to leg fatigue.33 This finding has been
described as a ‘‘shift in the locus of symptom limitation’’ at
maximum exercise. Relief of dyspnea seems to expose the
significant contribution of skeletal muscle dysfunction,
discussed earlier, in the limitation of physical activity,
which must be addressed together with lung mechanics in
the clinical management of the COPD patient.
While it is known that bronchodilators reduce opera-
tional lung volumes in the resting state (static hyperinfla-
tion), until recently their effects on dynamic hyperinflation
were unclear. One hypothesis was that because broncho-
dilators induced lower static lung volumes at rest, it took
longer for dynamic hyperinflation to occur, thereby
extending the dyspnea limit and prolonging exercise
endurance. O’Donnell et al.32 have shown this hypothesis toinflation, exercise and dyspnea.
Dynamic
b (mL)
D Exercise
endurance
D Dyspnea p value
330c þ618 sc Y <0.05 vs. room air
133 þ696 s NM <0.05 vs. pre-training
M [>10 W NM <0.02 vs. no surgery
M þ126 m Y <0.01 vs. BL
(dyspnea only)
M þ45 m NM <0.05 vs. BL
200 þ288 s Y <0.001 vs. air
M NM NM <0.05
170 þ170 Y 0.03 vs. no surgery
(exercise only)
ource: Ref. 8. Reproduced with permission].
Table 2 Effects of bronchodilators on hyperinflation, exercise and dyspnea.
Intervention Author n Baseline
FEV1 (%)
D Static
IC* (mL)
D Dynamic
ICy
D Exercise
endurance
D Dyspnea p value
Theophylline Chrystyn et al.47 33 29 þ190 NM þ56 m Y <0.001 vs. PLA
Albuterol Belman et al.52 13 39 þ350 NM NM Y <0.05 vs. PLA
Newton et al.48 281 SH 52 þ220 NM NM NM <0.001 vs. BL
676 MH 78 þ110 NM NM NM NS vs. BL
Salmeterol O’Donnell et al.32,33,49 23 42 þ330 þ170 þ90 s Y <0.05 vs. PLA
Ipatropium O’Donnell et al.50 29 40 þ450, þ330 þ390, þ290 þ168, þ66 s Y <0.05 vs. PLA
Tiotropium Celli et al.51 81 43 þ350 NM NM NM <0.01 vs. PLA
O’Donnell et al.32,33,49 187 44 þ230 þ180 þ105 Y <0.05 vs. PLA
Maltais et al.34 261 43 þ220, þ150 þ220, þ140 þ235 s, þ171 s Y <0.01 vs. PLA
Y
*IC measured during body plethysmography as total lung capacity minus functional residual capacity. þIC measured at isotime during
constant load submaximal exercise. MHZmoderately hyperinflated (TLCZ 115%e133% predicted); SHZ severely hyperinflated
(TLC> 133% of predicted); NMZ not measured. For those studies involving exercise, static IC measurements are reported after
administration of bronchodilator but before exercise. For the Maltais study, the first values represent changes 2.25 h following
administration of tiotropium and the second values represent changes at 8 h. [Source: Ref.8 Reproduced with permission.]
330 C.B. Cooperbe true by measuring inspiratory capacity at various stages
during sub-maximal constant work rate exercise tests and
demonstrating an increase with bronchodilator treatment.
Increases in inspiratory capacity increased exercise endur-
ance time by 21% as compared to placebo, and dyspnea
decreased by 0.9 0.3 units on the modified Borg scale.32 A
more recent study confirmed these findings by showing
comparable improvements in endurance time for sub-
maximum constant work rate post-treatment.34 Addition-
ally, this study showed significant, but reduced effects of
treatment 8 h post-dose. Collectively, these studies
demonstrate conclusively that improvements in hyperin-
flation, particularly with increases in inspiratory capacity,
do correlate with improvements in exercise endurance and
reductions in dyspnea upon exertion e effects that have
not correlated with FEV1 measurements alone. These
studies provide compelling evidence of the need to
consider disease progression in COPD not simply in terms of
a continuing decline in FEV1,
15 but also as a progressive
decline in exercise performance linked to the symptoms
that accompany dynamic hyperinflation.Exercise and disease progression in COPD
Although activity monitors are available for use in COPD
patients, most are impractical to use in daily medical
practice. In the clinical trial setting, however, one device,
a triaxial accelerometer (DynaPort Activity Monitor; McRo-
berts BV, The Hague, Netherlands), was used successfully to
compare physical activity patterns between patients with
COPD and age-matched healthy subjects.20 COPD patients
spent nearly half as much time walking compared to
healthy individuals (44 26 vs. 81 26 min/day;
p< 0.0001) and significantly less standing time (191 99 vs.
295 109 min/day; p< 0.0001). Movement intensity during
walking was also decreased (1.8 0.3 vs. 2.4 0.5 m/s2;
p< 0.0001).9 Stated differently, healthy subjects spent
more than half of their time walking or standing, but the
COPD patients spent less than one third of their time
walking and standing, and therefore much more time sittingor lying around. When these activity data were related to
the stage of disease severity, the most dramatic decline in
activity level was noted between healthy individuals and
those patients with COPD of GOLD stages 1 and 2 [F. Pitta,
personal communication]. This suggests a strong need for
focused research on the early pathophysiology of COPD that
leads to the decline in activity level, and the resulting
deleterious health consequences.
Increases in mortality associated with physical inactivity
were reported by Myers et al. who studied 6213 men over
the course of six years.11 After adjustment for age, the
peak exercise capacity measured in metabolic equivalents
(MET) was the strongest predictor of the risk of death
among both normal subjects and those with cardiovascular
disease. Exercise capacity, in fact, was a better predictor
of mortality than established risk factors for cardiovascular
disease. Each 1-MET increase in exercise capacity
conferred a 12% improvement in survival.11 These findings
support results from an earlier study assessing exercise
capacity as a predictor of mortality specifically in the
setting of COPD. Among 144 COPD patients who were fol-
lowed for five years, 31 died. VO2max was reported to be
the best predictor of mortality, independent of FEV1
measures and patient age.10 These findings have prompted
a call to action to address the serious global problem of
physical deconditioning, to which the COPD patient is
particularly susceptible. The prescription of exercise has
been incorporated into COPD guidelines,20,35 which have
been used to construct a therapy model based on staging of
COPD, shown in Fig. 4. Pulmonary rehabilitation, with
a focus on exercise training of the legs, acts to break the
vicious cycle of physical deconditioning, which through
increased lactic acidosis in turn increases the ventilatory
requirement during exercise, increases breathlessness,
decreases exercise capacity, and further worsens the
physical deconditioning caused by COPD.36 Equally impor-
tant as initiating a rehabilitation program is maintaining it;
without ongoing exercise maintenance, functional exercise
capacity and quality of life in COPD patients have been
shown to decline towards the end of one year, returning
towards baseline exercise capacity and worse quality of
Long-acting bronchodilator PLUS  rehabilitative exercise
I: Mild II: Moderate III: Severe IV: Very Severe
• FEV1/FVC < 0.70
• FEV1    80% predicted
• FEV1/FVC < 0.70
• 50%    FEV1< 80%
predicted 
• FEV1/FVC < 0.70
• 30%   FEV1< 50%
predicted 
• FEV1/FVC < 0.70
• FEV1< 30% predicted
or FEV1< 50%  
predicted plus chronic
respiratory failure 
Active reduction of risk factor(s); influenza vaccination
Add short-acting bronchodilator (when needed)
Add inhaled glucocorticosteroids if repeated
exacerbations
Add long-term oxygen
if chronic respiratory
failure. 
Consider surgical
treatments
Figure 4 Therapy based on staging of COPD. The ATS/ERS Task Force and original GOLD Guidelines were used together to
construct a therapy model based on the staging of COPD. For all patients with COPD (FEV1/FVC< 0.70), it is recommended that risk
factors be avoided and influenza vaccinations be given. At stage I (mild), short-acting bronchodilators should be added to risk-
factor avoidance and vaccination. Stage II (moderate) calls for the addition of a regular prescription of one or more long-acting
bronchodilators; at this time rehabilitative exercise should also be added to therapeutic intervention. At stage III (severe), it is
recommended that, along with other therapies mentioned, an inhaled corticosteroid also be prescribed if there are repeated
exacerbations. At stage IV (very severe), supplemental O2 should be used to counter chronic hypoxemia and surgery (LVRS or lung
transplantation) can be considered, in carefully selected cases. [Source: Global Intiative for Chronic Obstructive Lung Disease:
Executive Summary.20 Reproduced with permission.]
Airflow obstruction and exercise 331life.37 Pulmonary rehabilitation, therefore, should be for
life.
The exercise paradigm, however, needs to change for
patients with earlier COPD. Hospital-based programs, which
are high cost and resource intensive, are not appropriate for
these patients. Further, these patients may be working and
therefore not available during traditional hospital-based
rehabilitation hours. Pulmonary medicine can learn much
from the discipline of cardiology, which has restructured
programs and resources for myocardial infarction patients to
accommodate work schedules and other demands of daily
living. The author of this paper is undertaking studies of how
the use of personal trainers in health clubs in Los Angeles
impacts the health, outcomes, and survival of COPD patients
who embark on a physical training program at an early stage
of disease. Of particular interest is the impact on comor-
bidities that typically occur as a result of physical inactivity,
such as hypertension, atherosclerosis, dyslipidemia,
obesity, glucose intolerance, and depression. We are eager
to report the outcome of these trials in the years ahead.Addition of bronchodilator therapy to exercise
rehabilitation
Treatment with tiotropium during pulmonary rehabilitation
has been shown to markedly potentiate the beneficialeffects on exercise endurance.38 In a double-blind, placebo-
controlled trial, COPD patients participating in 8 weeks of
physical rehabilitation at 17 sites were randomized to
receive either tiotropium 18 mg daily (nZ 47) or placebo
(nZ 44). All patients were allowed to use the short-acting
bronchodilator albuterol as needed. Exercise endurance was
measured using a sub-maximal constant load exercise test
on a treadmill ergometer at 75% of maximum work rate.
Baseline measurements did not differ significantly between
groups. All of the patients improved their exercise endur-
ance as they progressed though eight weeks of structured
exercise training using target work rates. However, those
patients receiving the long-acting bronchodilator, experi-
enced clinically meaningful improvements in dyspnea and
health status compared to patients who underwent physical
rehabilitation alone. Mean differences in endurance time
(tiotropium minus placebo) prior to physical rehabilitation,
at the end of physical rehabilitation, and 12 weeks after
physical rehabilitation were 1.65 min (pZ 0.183), 5.35 min
(pZ 0.025), and 6.60 min (pZ 0.018), respectively. We are
led to the conclusion that improvements in ventilatory
mechanics from tiotropium permitted patients to perform
their exercise training at a higher intensity thus augmenting
the physiological benefits derived from pulmonary
rehabilitation.38
Exercise training in patients with COPD clearly improves
sub-maximal exercise endurance, possibly mediated by
332 C.B. Cooperdecreased dynamic hyperinflation.24 However, it is impor-
tant that exercise rehabilitation focus not only on improving
lung function, but alsomuscle strength. Aerobic activity is of
little value to the patient who is unable to get out of bed
because of muscle atrophy. The quadriceps, pectoralis
major, and latissimus dorsi muscles are all weaker in COPD
patients than in control subjects, and quadriceps strength
correlates with the degree of airflow obstruction.39 Resis-
tance training, as a means of improving skeletal muscle
strength, is a crucial component of exercise rehabilitation.40
However, like aerobic training, resistance training should be
scientifically based and focused on the larger agonist and
antagonist muscle groups, with attention to the overload
principle and appropriate progression of the resistance.41 In
men with COPD, who have high prevalence of low testos-
terone levels, the relative deficiency of testosterone may
contribute to muscle atrophy and weakness. There is some
evidence to suggest that combining testosterone with
resistance training in men with COPD may improve muscle
strength,40 and there have been other studies of anabolic
therapies in COPD showing increased fat-free mass and
exercise performance.4,14 Despite these findings, anabolic
supplementation is not generally recommended in evidence-
based guidelines.40 Several devices can be used to assist
ambulation in severe COPD including portable oxygen
systems and also walking frames. The physiological benefits
that accrue from using supplemental oxygen have already
been discussed. Ambulatory oxygen increases exercise
endurance in an experimental setting42 although longer-
term use has not been shown to improve quality of life.43
Consequently, the widespread use of portable oxygen,
especially in non-hypoxemic patients, remains somewhat
controversial. Inspiratory pressure support during exercise
has been shown to increase endurance time44 but the
cumbersome nature of apparatus for ventilatory assistance
will probably limit its practical application.42 Use of walking
frames has not been scientifically evaluated although the
addition of occupational therapy to conventional pulmonary
rehabilitation program has been shown to improve specific
outcomes that relate to activities of daily living.45Conclusions
Approaches to maintaining physical activity in COPD must
be centered around the most effective therapies. To date,
the medical evidence suggests that the combination of
long-acting bronchodilator therapy combined with struc-
tured exercise prescriptions is the most beneficial
approach. Exercise therapy should begin as early as
possible in the disease process. However, current struc-
tured programs are primarily hospital-based and are not
conducive to use by patients in early stage disease who
require more flexible hours and outpatient resources. More
severe patients can be assisted in some degree of physical
activity with support from lightweight portable oxygen
systems, which have been shown to prolong survival41 and
devices to assist in ambulation. The medical evidence
reveals that physical activity improves exercise capacity
and that this is associated with prolonged survival. The
extent to which physical activity decreases exacerbations is
unclear but is an area worthy of additional study.Conflict of interest
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